image: T cell-selective coating and protection strategy with a flexible DNA network formed by rolling circle amplification, which promotes T-cell aggregation and activation for anti-tumor therapy. view more
Credit: APSB
Adoptive cell therapy (ACT) is an emerging powerful cancer immunotherapy, which includes a complex process of genetic modification, stimulation and expansion. During in vitro or ex vivo manipulation, sensitive cells are inescapably subjected to harmful external stimuli. Although a variety of cytoprotection strategies have been developed, their application on ACT remains challenging.
The authors of this article constructed a DNA network on cell surface by rolling circle amplification (RCA), and used T cell-targeted trivalent tetrahedral DNA nanostructure as a rigid scaffold to achieve high-efficient and selective coating for T cells. The cytoprotective DNA network on T-cell surface made them aggregate over time to form cell clusters, which exhibited more resistance to external stimuli and enhanced activities in human peripheral blood mononuclear cells and liver cancer organoid killing model.
The authors of this article demonstrate a novel strategy for in vitro T cell-selective protection, which has a great potential for application in ACT.
Article reference: Ziyan Zhang, Qiaojuan Liu, JizhouTan et al., Coating with flexible DNA network enhanced T-cell activation and tumor killing for adoptive cell therapy, Acta Pharmaceutica Sinica B, 2021, ISSN 2211-3835, https://doi.org/10.1016/j.apsb.2021.04.002
Keywords: Cell surface engineering, Selective cytoprotection, DNA nanostructure, Tetrahedral DNA nanostructure, Rolling circle amplification, Adoptive cell therapy, T cell, Tumor-killing
# # # # # #
The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association.
For more information please visit https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/
Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board
APSB is available on ScienceDirect (https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).
Submissions to APSB may be made using Editorial Manager® (https://www.editorialmanager.com/apsb/default.aspx).
CiteScore: 12.5
Impact Factor: 11.413
ISSN 2211-3835
# # # # #